Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET
NCT02058043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2018-02-19
Summary
DESCRIPTION OF RELATED QUESTION Cognitive disorders are frequently encountered and present a major public health problem given the aging of the population.
There is not one, but several neurodegenerative pathologies individual differentiated.
Particularly distinguished is Alzheimer's disease (the most common), dementia lobar fronto-temporal associated with semantic dementia (a disease with a particular tropism for semantic memory and the anterior temporal lobe), and dementia with Lewy bodies.
To differentiate these pathologies is, for the clinician, is a major issue and the clinic may not be enough.
The management and current diagnostics of atypical cognitive disorders, that is to say, patients with clinical symptoms or neuropsychological testing results suggestive of a neurodegenerative disorder other than Alzheimer's disease, are based largely on data imaging.
In the first intention, conducting imaging by MRI is recommended by the HAS, particularly to search for treatable causes to these cognitive disorders (tumors, intracranial hemorrhage in particular) but also to study the distribution of cerebral atrophy.
The sequences used are the sequences 3D T1, axial Flair, gradient echo axial T2 and coronal T2 in the plane of hippocampi and also diffusion imaging.
Research has shown interest in the study of cerebral perfusion in cognitive disorders.
The HAS recommends not to inject contrast medium on MRI in this context. The sequence of perfusion by tagging arterial protons or "arterial spin labeling" (ASL) does not use exogenous contrast medium. This is available as a commercial product, CE marked, on most of the recent clinical MRI scanners. This non-invasive technique, requiring no special precautions (e.g. verification of renal function) is used in routine clinical practice at the University Hospital of Rennes and in many centers. In the imaging of patients with dementia, it is widely used as well as the 3D T1 sequences or diffusion imaging (International Initiative ADNI) and is subject to optimization and harmonization of use in routine clinical practice with the European COST AID actions.
The second intention, an isotope imaging by FDG-PET or study of perfusion SPECT can also be performed. The interest of isotopic imaging (FDG-PET and SPECT) lies in the provision of information metabolic nonexistent in MRI, with a superiority of FDG-PET compared with SPECT. FDG-PET is the preferred examination and is carried out at CRLCC Eugène Marquis de Rennes in this context.
The aim of our study is to compare the imaging of TEPFDG, a technique not morphological, and ASL that, even if they do not study the same mode (metabolism for the first and perfusion for the second) may depict consistent anomalies.
Conditions
- Atypical Cognitive Disorders
Sponsors & Collaborators
-
Rennes University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-11-30
- Primary Completion
- 2017-12-31
- Completion
- 2017-12-31
Countries
- France
Study Locations
More Related Trials
-
Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment
NCT00684281 ·Status: COMPLETED ·Phase: NA
-
Prospective Memory Imaging
NCT01638884 ·Status: UNKNOWN ·Phase: NA
-
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
NCT04150198 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects
NCT00951197 ·Status: COMPLETED
-
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259 ·Status: COMPLETED ·Phase: PHASE2
-
Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)
NCT00637442 ·Status: UNKNOWN ·Phase: NA
-
Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders
NCT00001362 ·Status: COMPLETED
-
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
NCT00413621 ·Status: COMPLETED
-
Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion
NCT02353884 ·Status: COMPLETED
-
Isotopic Imaging for Prodromal Alzheimer's Disease
NCT01231295 ·Status: COMPLETED
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
NCT01815112 ·Status: TERMINATED ·Phase: NA
-
Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers
NCT01238458 ·Status: UNKNOWN ·Phase: PHASE2
-
Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology
NCT02353845 ·Status: COMPLETED
-
Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study
NCT05806697 ·Status: RECRUITING ·Phase: NA
-
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
NCT06254469 ·Status: RECRUITING ·Phase: PHASE3
-
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
NCT07115238 ·Status: RECRUITING ·Phase: PHASE3
-
Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
NCT07089303 ·Status: RECRUITING
-
Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder
NCT00029120 ·Status: COMPLETED
-
Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET
NCT04804722 ·Status: COMPLETED
-
MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease
NCT06099587 ·Status: RECRUITING ·Phase: NA
-
A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test
NCT01322373 ·Status: UNKNOWN
-
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
NCT06618872 ·Status: RECRUITING ·Phase: NA
-
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
NCT06120049 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Early Detection of Mild Cognitive Impairment in Individual Patients
NCT00243451 ·Status: COMPLETED